2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1718

Cost Effectiveness of Nurse-Led Care for People with Rheumatoid Arthritis: A Multicentre RCT
Abstract Number: 1829

Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Abstract Number: 1168

Cost-Effectiveness Analysis of Early Biologic Treatment in Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 2637

Cost-Effectiveness and Cost-Utility Analysis of Treat-to-Target Versus Usual Care in Early Rheumatoid Arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring Registry
Abstract Number: 1966

Cost-Effectiveness of Bazedoxifene Compared with Raloxifene in the Treatment of Postmenopausal Osteoporotic Women
Abstract Number: 2461

Cost-Effectiveness of Systemic Therapies for Acute Gouty Arthritis
Abstract Number: 2646

Cost-Effectiveness of Tai Chi Mind-Body Exercise for the Treatment of Fibromyalgia
Abstract Number: 2463

Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis
Abstract Number: 2509

Cost-Effectiveness of Training Rural Providers to Perform Joint Injections
Abstract Number: 2464

Cost-Sharing and Utilization of Biologic and Non-Biologic Dmards Among U.S. Medicare Beneficiaries with Rheumatoid Arthritis
Abstract Number: 386

Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Abstract Number: 1647

Critical Management Decisions in Cardiac Neonatal Lupus: The Role of Fluorinated Steroids
Abstract Number: 1510

Critical Role of the Adhesion Receptor Dnax Accessory Molecule-1 (DNAM-1) in the Development of Inflammation-Driven Dermal Fibrosis in Mouse Model of Systemic Sclerosis
Abstract Number: 2236

Cross Cultural Validation of English and French Versions of a Disease Specific Patient Reported Outcome Measure for Lupus in Canada
Abstract Number: 2537

Cross-Sectional and Longitudinal Associations Between Circulating Leptin and Knee Cartilage Thickness in Older Adults

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].